Gougeon J
Sem Hop. 1983 Dec 12;59(46):3246-8.
This comparative trial, in which each patient acts as his own control, is an ideal model for comparing the effectiveness of both products. None of the criteria studied demonstrated a statistically significant difference in effectiveness between the two agents. Under the conditions of this study, Bi-Profenid and indomethacin can therefore be considered as having comparable potency. Study of tolerance demonstrated a superiority of Bi-Profenid over indomethacin, with excellent results in 72.5% and 66.1% of cases respectively. Specifically, digestive and above all neuro-sensory tolerance was better with Bi-Profenid. Osteoarthritis is a good indication for these medications whose effectiveness is well documented.
这项对比试验中,每位患者自身作为对照,是比较两种产品有效性的理想模型。所研究的各项标准均未显示出两种药物在有效性上有统计学显著差异。因此,在本研究条件下,必洛芬酯和吲哚美辛可被视为具有相当的效力。耐受性研究表明必洛芬酯优于吲哚美辛,分别在72.5%和66.1%的病例中取得了优异结果。具体而言,必洛芬酯在消化方面,尤其是神经感觉耐受性方面表现更佳。骨关节炎是这些药物的一个良好适应症,其有效性已有充分记录。